271 related articles for article (PubMed ID: 22801464)
1. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Coleman RE
Curr Opin Support Palliat Care; 2012 Sep; 6(3):322-9. PubMed ID: 22801464
[TBL] [Abstract][Full Text] [Related]
2. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
3. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
4. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Gnant M
Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
[TBL] [Abstract][Full Text] [Related]
5. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
6. The use of bisphosphonates in cancer treatment.
Coleman R
Ann N Y Acad Sci; 2011 Feb; 1218():3-14. PubMed ID: 20946581
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in the adjuvant treatment of breast cancer.
Winter MC; Coleman RE
Clin Oncol (R Coll Radiol); 2013 Feb; 25(2):135-45. PubMed ID: 23207072
[TBL] [Abstract][Full Text] [Related]
12. The metastatic microenvironment of breast cancer: clinical implications.
Coleman RE; Gregory W; Marshall H; Wilson C; Holen I
Breast; 2013 Aug; 22 Suppl 2():S50-6. PubMed ID: 24074793
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Coleman RE
Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
[TBL] [Abstract][Full Text] [Related]
14. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
15. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Carter JA; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
17. Preventing bone complications in prostate cancer.
Bishr M; Saad F
Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
19. Bone-modifying agents as adjuvant therapy for early-stage breast cancer.
Figueroa-Magalhães MC; Miller RS
Oncology (Williston Park); 2012 Oct; 26(10):955-62. PubMed ID: 23176008
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid in the treatment of metastatic breast cancer.
Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
